Drug intelligence / Profile preview

Alamin SE Injection

Development stage
Unknown
Lead developer
Albert David
Modality
Small Molecules
Administration
Intravenous, Parenteral
01

Overview

Alamin SE Injection is a specialized parenteral nutritional formulation developed and manufactured by Albert David. It is a sterile, non-pyrogenic aqueous solution containing a balanced mixture of 17 essential and non-essential amino acids (8% w/v), supplemented with electrolytes and sorbitol. The formulation is indicated for the prevention and treatment of nitrogen loss and negative nitrogen balance in patients where oral or enteral nutrition is inadequate, impossible, or contraindicated, such as in cases of severe trauma, major surgery, or gastrointestinal malabsorption. The inclusion of electrolytes (sodium, potassium, magnesium, chloride, and acetate) helps maintain fluid and acid-base balance, while sorbitol serves as a non-glucose carbohydrate energy source to support metabolic requirements during parenteral therapy.

Brand names
Alamin SE InjectionAlamin SE
Other names
Amino Acids 8% with Electrolytes and Sorbitol Injection

Beyond the preview

Go deeper on Alamin SE Injection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alamin SE Injection.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call